Obesity is a disease. The American Medical Association said so almost a decade ago, and experts convened by the National Institutes of Health did the same when Bill Clinton was president. But it bears repeating, because the conventional wisdom still holds that obesity is a choice. From paleo to Pilates, get-fit-quick schemes revolve around willpower and the assumption that weight loss is entirely a function of diet and exercise. Successful weight loss is partly a function of behavior, yes, but research suggests that genetics and environmental factors can make it extremely difficult or even impossible for some people without outside help. Today, outside help often means surgery, but there’s a much less invasive option quietly sitting on the shelf.
That would be prescription drugs, especially a group of drugs known as GLP-1 receptor agonists, or GLP-1s. These compounds were designed for people with diabetes but have also been shown to cause patients to shed pounds. They simulate a hormone known as glucagon-like peptide 1, the chemical that helps people feel full after they eat. Many people taking a newer GLP-1 drug for weight loss known as Saxenda, for example, lose at least 5% of their body weight, according to one study by the manufacturer. Older generic medications can cost patients as little as $15 a month, while new, brand-name GLP-1s run about $1,400 for a month’s supply of weekly injections.
Bu hikaye Bloomberg Businessweek dergisinin January 10, 2022 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Bloomberg Businessweek dergisinin January 10, 2022 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Instagram's Founders Say It's Time for a New Social App
The rise of AI and the fall of Twitter could create opportunities for upstarts
Running in Circles
A subscription running shoe program aims to fight footwear waste
What I Learned Working at a Hawaiien Mega-Resort
Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.
How Noma Will Blossom In Kyoto
The best restaurant in the world just began its second pop-up in Japan. Here's what's cooking
The Last-Mover Problem
A startup called Sennder is trying to bring an extremely tech-resistant industry into the age of apps
Tick Tock, TikTok
The US thinks the Chinese-owned social media app is a major national security risk. TikTok is running out of ways to avoid a ban
Cleaner Clothing Dye, Made From Bacteria
A UK company produces colors with less water than conventional methods and no toxic chemicals
Pumping Heat in Hamburg
The German port city plans to store hot water underground and bring it up to heat homes in the winter
Sustainability: Calamari's Climate Edge
Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment
New Money, New Problems
In Naples, an influx of wealthy is displacing out-of-towners lower-income workers